Samsung Biologics on Friday reported an operating profit of 983.6 billion won ($796.4 million) in 2022 on a consolidated basis, up 83% from the previous year, with sales soaring 91% to 3 trillion won.
Samsung Biologics Co., the world’s top contract drugmaker, said its profit almost doubled last year thanks to more orders as its sales surged after acquiring a nearly 50% stake in a biosimilar joint venture with Biogen Inc.
RECORD SALES ON HEALTHY ORDERSOn a separate basis, Samsung Biologics said its operating profit jumped 80% to 968.1 billion won as sales leaped 55% to a record high of 2.4 trillion won.
BEAMSTART brings you the latest news, database, and jobs from all around the world on startups, technology, and business. Stay updated with industry news, plug-in to exciting community events, and discover incredible career opportunities with the world's most innovative companies.